- Scopus BioPharma Inc SCPS has launched Duet Therapeutics that integrates the management and clinical development of the immunotherapy assets of Scopus and Olimmune.
- Related Content: Scopus BioPharma Adds Oligonucleotide Cancer Therapeutics With Olimmune Acquisition.
- The Duet Platform is comprised of three technologies, including RNA silencing (DUET-01), Antisense (DUET-02), and Protein degradation (DUET-03).
- DUET-01 is in Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma.
- In 2022, Duet is targeting to file two INDs for DUET-02 in two separate indications: genitourinary and head & neck cancers.
- Duet is also evaluating combination therapies with checkpoint inhibitors.
- Price Action: SCPS stock is up 30.50% at $6.54 during the market session on the last check Thursday, before the trading was halted.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
